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Arch Dis Child (1991) 66:966-970 Progressive renal toxicity due to ifosfamide D. Heney, J. Wheeldon, E Rushworth, C. Chapman, I. J. Lewis, and A prospective and follow up study of renal tubular and glomerular function in 11 children receiving ifosfamide treatment was conducted. Each child received between four and 14 courses of ifosfamide, given as a continuous infusion of 3 g/m 2 over 24 hours for two or three days. Evidence of renal toxicity was seen in all patients. There was a treatment related rise in urinary tubular markers (N-acetyl-glucosaminidase and cza microglobulin). Recovery was limited, so that by the fourth course of treatment all values remained abnormal. There was: an associated treat-C. C. Bailey ment related reduction in plasma phosphate concentration. Urinary albumin also showed a treatment related rise, but with fewer abnormal values. Electrophoresis was used to confirm tubular or glomerular patterns. Glomemlar toxicity was less severe and occurred in fewer patients. The follow up study showed persistence of tubular damage in all seven patients examined, and there was evidence of glomerular damage in five of the seven children. Children receiving ifosfamide need to be carefully monitored for renal toxicity both during treatment and at follow up.
Arch Dis Child (1991 Child ( ) 66: 1213 Child ( -1216 Prediction of blood pressure from plasma renin activity in reflux nephropathy I-I. Jardim, V. Shah, J. M. Savage, T. M. Barratt, and M. J. Dillon
As there is a 10% risk of hypertension developing in children with reflux nephropathy and the renin-angiotensin system has been implicated in its aetiology, a long term prospective study has been undertaken to explore the relationship between plasma renin activity (PRA) and blood pressure in such patients. In 1978, of 100 normotensive children with reflux nephmpathy 8% were shown to have PRA above normal. Five years later of 85 subjects suitable for analysis 13% had increased PRA and it was shown that PRA and blood pressure SD scores significantly increased. The present study refers to the 10 year follow up in which 95 of the original group were traced but eight of these were unavailable for study and 28 others were excluded from analysis because of extraneous factors that might influence blood pressure or PRA. Results therefore on 59 have been analysed. PRA was above normal in 13/59 (20%) subjects, and PRA and blood pressure SD scores had further increased. The data continue to support the role of the renin-angiotensin system in the observed rise of blood pressure in reflux nephropathy, but individual PRA measurements do not appear so far to predict reliably the onset of hypertension in affected patients. The single-dose pharmacokinetics of recombinant human erythropoietin (rHuEpo; 40 units/kg 1) were investigated in children (9-16 years) with end-stage renal failure. After an intravenous (i. v.) dose, serum rHuEpo concentrations declined in a monoexponential manner with a mean halflife (h/2) of 5.6 + 3 h ( + SEM; n = 9). Serum clearance and the apparent volume of distribution were estimated to be 10.1 +0.9 ml h-lkg -1 and 79.5 4-5.0 ml kg -1 (n = 9) respectively. Subcutaneous (s. c.) delivery resulted in serum values that peaked at 10 h, and thereafter concentrations declined slowly with a ti/2 of 21.1 4-4.5 h (n = 9). Serum rHuEpo concerttrations were maximal at 14 h after i.p. administration and the tl/2 was 9.5 _+ 1.0 h (n = 3). The mean fraction absorbed of SC rHuEpo was 0.40 whereas after i.p. administration this fraction was only 0.17. These results show that after both s.c. and i.p. delivery, disposition of the hormone is rate-limited by absorption, and bioavailability for these extravascular routes is poor. In addition, comparison of the results with those available for adults indicates that rHuEpo is better absorbed but more rapidly cleared in children.
